Calmodulin regulates the transcriptional activity of estrogen receptors - Selective inhibition of calmodulin function in subcellular compartments

被引:23
作者
Li, L
Li, ZA
Sacks, DB
机构
[1] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
D O I
10.1074/jbc.M210708200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The steroid hormone estrogen elicits biological effects in cells by binding to and activating the estrogen receptor (ER). Estrogen binding induces a conformational change in the receptor, inducing nuclear translocation and transcriptional activation of ER. The ubiquitous Ca2+-binding protein calmodulin has been shown to interact directly with ER and enhance its stability. To further elucidate the functional sequelae of the association between calmodulin and ER, we examined the effect on ER transcriptional activation of specifically inhibiting calmodulin. The cell-permeable calmodulin antagonist CGS9343B prevented estrogen-induced transcriptional activation by ER, without altering basal transcription. The inhibition was dose-dependent and independent of the time of estrogen stimulation. To validate these findings, calmodulin function was also neutralized by targeted expression of a specific inhibitor peptide. By inserting localization signals, the inhibitor peptide was selectively targeted to different subcellular domains. Inactivation of calmodulin function in the nucleus virtually eliminated estrogen-stimulated ER transcriptional activation. By contrast, when membrane calmodulin was specifically neutralized, estrogen-stimulated transcriptional activation by ER was only slightly attenuated. Importantly, the inhibitor peptides did not significantly reduce the amount of ER in the cells. Together, these data demonstrate that calmodulin is a fundamental component of ER transcriptional activation.
引用
收藏
页码:1195 / 1200
页数:6
相关论文
共 30 条
[21]  
NORMAN JA, 1987, MOL PHARMACOL, V31, P535
[22]   Basic helix-loop-helix protein sequences determining differential inhibition by calmodulin and S-100 proteins [J].
Onions, J ;
Hermann, S ;
Grundstrom, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (38) :23930-23937
[23]  
Pedrero JMG, 2002, MOL ENDOCRINOL, V16, P947
[24]   MONOCLONAL-ANTIBODY TO CALMODULIN - DEVELOPMENT, CHARACTERIZATION, AND COMPARISON WITH POLYCLONAL ANTICALMODULIN ANTIBODIES [J].
SACKS, DB ;
PORTER, SE ;
LADENSON, JH ;
MCDONALD, JM .
ANALYTICAL BIOCHEMISTRY, 1991, 194 (02) :369-377
[25]  
STROBL JS, 1992, J PHARMACOL EXP THER, V263, P186
[26]   DY-9760e, a novel calmodulin antagonist with cytoprotective action [J].
Sugimura, M ;
Sato, T ;
Nakayama, W ;
Morishima, Y ;
Fukunaga, K ;
Omitsu, M ;
Miyamoto, E ;
Shirasaki, Y .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 336 (01) :99-106
[27]  
TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315
[28]   Functional elimination of calmodulin within the nucleus by targeted expression of an inhibitor peptide [J].
Wang, JH ;
Campos, B ;
Jamieson, GA ;
Kaetzel, MA ;
Dedman, JR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (51) :30245-30248
[29]  
WEI JW, 1983, CANCER CHEMOTH PHARM, V11, P86
[30]   Coactivator and corepressor complexes in nuclear receptor function [J].
Xu, L ;
Glass, CK ;
Rosenfeld, MG .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1999, 9 (02) :140-147